| . | Total cohort (n = 1455) . | Fangcang shelter hospital group (n = 283) . | Designated hospital group (n = 1172) . |
|---|---|---|---|
| Age | |||
| Mean age (SD), years | 58.3 (12.3) | 52.8 (10.4) | 59.7 (12.3) |
| 18–39 | 127 (8.7%) | 38 (13.4%) | 89 (7.6%) |
| 40–59 | 578 (39.7%) | 157 (55.5%) | 421 (35.9%) |
| ≥60 | 750 (51.6%) | 88 (31.1%) | 662 (56.5%) |
| Gender | |||
| Male | 609 (41.9%) | 111 (39.2%) | 498 (42.5%) |
| Female | 846 (58.1%) | 172 (60.8%) | 674 (57.5%) |
| Marital status | |||
| Married | 1221 (83.9%) | 239 (84.5%) | 982 (83.8%) |
| Non-married | 234 (16.1%) | 44 (5.7%) | 190 (2.6%) |
| Education | |||
| Middle or lower | 1039 (71.4%) | 190 (67.1%) | 849 (72.4%) |
| College or higher | 416 (28.6%) | 93 (32.9%) | 323 (27.6%) |
| Smoking | |||
| Yes | 188 (12.9%) | 41 (14.5%) | 147 (12.5%) |
| No | 1267 (87.1%) | 242 (85.5%) | 1025 (87.5%) |
| Family income (thousand RMB per year) | |||
| <60 | 879 (60.4%) | 160 (56.5%) | 719 (61.3%) |
| ≥60 | 576 (39.6%) | 123 (43.5%) | 453 (38.7%) |
| Comorbidities | 826 (56.8%) | 119 (42.0%) | 707 (60.3%) |
| Bronchial diseases | 61 (4.2%) | 6 (2.1%) | 55 (4.7%) |
| Cancers | 25 (1.7%) | 7 (2.5%) | 18 (1.5%) |
| Cardiovascular and cerebrovascular diseases | 518 (35.6%) | 64 (22.6%) | 454 (38.7%) |
| Chronic kidney diseases | 30 (2.1%) | 5 (1.8%) | 25 (2.1%) |
| Diabetes | 229 (15.7%) | 27 (9.5%) | 202 (17.2%) |
| Digestive diseases | 113 (7.8%) | 23 (8.1%) | 90 (7.7%) |
| Other diseases | 210 (14.4%) | 34 (12%) | 176 (15.0%) |
| Illness severity | |||
| Asymptomatic | 73 (5.0%) | 26 (9.2%) | 47 (4%) |
| Mild | 1032 (70.9%) | 237 (83.7%) | 795 (67.8%) |
| Moderate | 144 (9.9%) | 11 (3.9%) | 133 (11.3%) |
| Severe or critical | 206 (14.2%) | 9 (3.2%)a | 197 (16.8%) |
| Acute phase symptoms | |||
| Fever | 989 (68.0%) | 177 (62.5%) | 812 (69.3%) |
| Cough | 702 (48.2%) | 138 (48.8%) | 564 (48.1%) |
| Dyspnea | 451 (31.0%) | 48 (17.0%) | 403 (34.4%) |
| Fatigue | 692 (47.6%) | 109 (38.5%) | 583 (49.7%) |
| Nausea or vomiting | 158 (10.9%) | 31 (11.0%) | 127 (10.8%) |
| Diarrhea | 334 (23.0%) | 70 (24.7%) | 264 (22.5%) |
| Myalgia | 292 (20.1%) | 52 (18.4%) | 240 (20.5%) |
| Smell disorders | 158 (10.9%) | 22 (7.8%) | 136 (11.6%) |
| Taste disorders | 267 (18.4%) | 46 (16.3%) | 221 (18.9%) |
| Time from symptom onset to follow-up, months | 16.9 (1.3) | 17.0 (1.3) | 16.9 (1.2) |
| COVID-19 vaccinationb | 902 (62.0%) | 186 (65.7%) | 716 (61.1%) |
| . | Total cohort (n = 1455) . | Fangcang shelter hospital group (n = 283) . | Designated hospital group (n = 1172) . |
|---|---|---|---|
| Age | |||
| Mean age (SD), years | 58.3 (12.3) | 52.8 (10.4) | 59.7 (12.3) |
| 18–39 | 127 (8.7%) | 38 (13.4%) | 89 (7.6%) |
| 40–59 | 578 (39.7%) | 157 (55.5%) | 421 (35.9%) |
| ≥60 | 750 (51.6%) | 88 (31.1%) | 662 (56.5%) |
| Gender | |||
| Male | 609 (41.9%) | 111 (39.2%) | 498 (42.5%) |
| Female | 846 (58.1%) | 172 (60.8%) | 674 (57.5%) |
| Marital status | |||
| Married | 1221 (83.9%) | 239 (84.5%) | 982 (83.8%) |
| Non-married | 234 (16.1%) | 44 (5.7%) | 190 (2.6%) |
| Education | |||
| Middle or lower | 1039 (71.4%) | 190 (67.1%) | 849 (72.4%) |
| College or higher | 416 (28.6%) | 93 (32.9%) | 323 (27.6%) |
| Smoking | |||
| Yes | 188 (12.9%) | 41 (14.5%) | 147 (12.5%) |
| No | 1267 (87.1%) | 242 (85.5%) | 1025 (87.5%) |
| Family income (thousand RMB per year) | |||
| <60 | 879 (60.4%) | 160 (56.5%) | 719 (61.3%) |
| ≥60 | 576 (39.6%) | 123 (43.5%) | 453 (38.7%) |
| Comorbidities | 826 (56.8%) | 119 (42.0%) | 707 (60.3%) |
| Bronchial diseases | 61 (4.2%) | 6 (2.1%) | 55 (4.7%) |
| Cancers | 25 (1.7%) | 7 (2.5%) | 18 (1.5%) |
| Cardiovascular and cerebrovascular diseases | 518 (35.6%) | 64 (22.6%) | 454 (38.7%) |
| Chronic kidney diseases | 30 (2.1%) | 5 (1.8%) | 25 (2.1%) |
| Diabetes | 229 (15.7%) | 27 (9.5%) | 202 (17.2%) |
| Digestive diseases | 113 (7.8%) | 23 (8.1%) | 90 (7.7%) |
| Other diseases | 210 (14.4%) | 34 (12%) | 176 (15.0%) |
| Illness severity | |||
| Asymptomatic | 73 (5.0%) | 26 (9.2%) | 47 (4%) |
| Mild | 1032 (70.9%) | 237 (83.7%) | 795 (67.8%) |
| Moderate | 144 (9.9%) | 11 (3.9%) | 133 (11.3%) |
| Severe or critical | 206 (14.2%) | 9 (3.2%)a | 197 (16.8%) |
| Acute phase symptoms | |||
| Fever | 989 (68.0%) | 177 (62.5%) | 812 (69.3%) |
| Cough | 702 (48.2%) | 138 (48.8%) | 564 (48.1%) |
| Dyspnea | 451 (31.0%) | 48 (17.0%) | 403 (34.4%) |
| Fatigue | 692 (47.6%) | 109 (38.5%) | 583 (49.7%) |
| Nausea or vomiting | 158 (10.9%) | 31 (11.0%) | 127 (10.8%) |
| Diarrhea | 334 (23.0%) | 70 (24.7%) | 264 (22.5%) |
| Myalgia | 292 (20.1%) | 52 (18.4%) | 240 (20.5%) |
| Smell disorders | 158 (10.9%) | 22 (7.8%) | 136 (11.6%) |
| Taste disorders | 267 (18.4%) | 46 (16.3%) | 221 (18.9%) |
| Time from symptom onset to follow-up, months | 16.9 (1.3) | 17.0 (1.3) | 16.9 (1.2) |
| COVID-19 vaccinationb | 902 (62.0%) | 186 (65.7%) | 716 (61.1%) |
Data are numbers (%) or means (SD). aAll nine severe patients were infected at the early stage of the epidemic and were home-isolated because of the limited supply of medical resources, including hospital beds. These patients moved to Fangcang shelter hospitals starting on February 2020. bSince April 2021, the Chinese government has encouraged those who have recovered from COVID-19 to take SARS-CoV-2 vaccines; therefore, all those who recovered in this study received SARS-CoV-2 vaccines after their infection.
| . | Total cohort (n = 1455) . | Fangcang shelter hospital group (n = 283) . | Designated hospital group (n = 1172) . |
|---|---|---|---|
| Age | |||
| Mean age (SD), years | 58.3 (12.3) | 52.8 (10.4) | 59.7 (12.3) |
| 18–39 | 127 (8.7%) | 38 (13.4%) | 89 (7.6%) |
| 40–59 | 578 (39.7%) | 157 (55.5%) | 421 (35.9%) |
| ≥60 | 750 (51.6%) | 88 (31.1%) | 662 (56.5%) |
| Gender | |||
| Male | 609 (41.9%) | 111 (39.2%) | 498 (42.5%) |
| Female | 846 (58.1%) | 172 (60.8%) | 674 (57.5%) |
| Marital status | |||
| Married | 1221 (83.9%) | 239 (84.5%) | 982 (83.8%) |
| Non-married | 234 (16.1%) | 44 (5.7%) | 190 (2.6%) |
| Education | |||
| Middle or lower | 1039 (71.4%) | 190 (67.1%) | 849 (72.4%) |
| College or higher | 416 (28.6%) | 93 (32.9%) | 323 (27.6%) |
| Smoking | |||
| Yes | 188 (12.9%) | 41 (14.5%) | 147 (12.5%) |
| No | 1267 (87.1%) | 242 (85.5%) | 1025 (87.5%) |
| Family income (thousand RMB per year) | |||
| <60 | 879 (60.4%) | 160 (56.5%) | 719 (61.3%) |
| ≥60 | 576 (39.6%) | 123 (43.5%) | 453 (38.7%) |
| Comorbidities | 826 (56.8%) | 119 (42.0%) | 707 (60.3%) |
| Bronchial diseases | 61 (4.2%) | 6 (2.1%) | 55 (4.7%) |
| Cancers | 25 (1.7%) | 7 (2.5%) | 18 (1.5%) |
| Cardiovascular and cerebrovascular diseases | 518 (35.6%) | 64 (22.6%) | 454 (38.7%) |
| Chronic kidney diseases | 30 (2.1%) | 5 (1.8%) | 25 (2.1%) |
| Diabetes | 229 (15.7%) | 27 (9.5%) | 202 (17.2%) |
| Digestive diseases | 113 (7.8%) | 23 (8.1%) | 90 (7.7%) |
| Other diseases | 210 (14.4%) | 34 (12%) | 176 (15.0%) |
| Illness severity | |||
| Asymptomatic | 73 (5.0%) | 26 (9.2%) | 47 (4%) |
| Mild | 1032 (70.9%) | 237 (83.7%) | 795 (67.8%) |
| Moderate | 144 (9.9%) | 11 (3.9%) | 133 (11.3%) |
| Severe or critical | 206 (14.2%) | 9 (3.2%)a | 197 (16.8%) |
| Acute phase symptoms | |||
| Fever | 989 (68.0%) | 177 (62.5%) | 812 (69.3%) |
| Cough | 702 (48.2%) | 138 (48.8%) | 564 (48.1%) |
| Dyspnea | 451 (31.0%) | 48 (17.0%) | 403 (34.4%) |
| Fatigue | 692 (47.6%) | 109 (38.5%) | 583 (49.7%) |
| Nausea or vomiting | 158 (10.9%) | 31 (11.0%) | 127 (10.8%) |
| Diarrhea | 334 (23.0%) | 70 (24.7%) | 264 (22.5%) |
| Myalgia | 292 (20.1%) | 52 (18.4%) | 240 (20.5%) |
| Smell disorders | 158 (10.9%) | 22 (7.8%) | 136 (11.6%) |
| Taste disorders | 267 (18.4%) | 46 (16.3%) | 221 (18.9%) |
| Time from symptom onset to follow-up, months | 16.9 (1.3) | 17.0 (1.3) | 16.9 (1.2) |
| COVID-19 vaccinationb | 902 (62.0%) | 186 (65.7%) | 716 (61.1%) |
| . | Total cohort (n = 1455) . | Fangcang shelter hospital group (n = 283) . | Designated hospital group (n = 1172) . |
|---|---|---|---|
| Age | |||
| Mean age (SD), years | 58.3 (12.3) | 52.8 (10.4) | 59.7 (12.3) |
| 18–39 | 127 (8.7%) | 38 (13.4%) | 89 (7.6%) |
| 40–59 | 578 (39.7%) | 157 (55.5%) | 421 (35.9%) |
| ≥60 | 750 (51.6%) | 88 (31.1%) | 662 (56.5%) |
| Gender | |||
| Male | 609 (41.9%) | 111 (39.2%) | 498 (42.5%) |
| Female | 846 (58.1%) | 172 (60.8%) | 674 (57.5%) |
| Marital status | |||
| Married | 1221 (83.9%) | 239 (84.5%) | 982 (83.8%) |
| Non-married | 234 (16.1%) | 44 (5.7%) | 190 (2.6%) |
| Education | |||
| Middle or lower | 1039 (71.4%) | 190 (67.1%) | 849 (72.4%) |
| College or higher | 416 (28.6%) | 93 (32.9%) | 323 (27.6%) |
| Smoking | |||
| Yes | 188 (12.9%) | 41 (14.5%) | 147 (12.5%) |
| No | 1267 (87.1%) | 242 (85.5%) | 1025 (87.5%) |
| Family income (thousand RMB per year) | |||
| <60 | 879 (60.4%) | 160 (56.5%) | 719 (61.3%) |
| ≥60 | 576 (39.6%) | 123 (43.5%) | 453 (38.7%) |
| Comorbidities | 826 (56.8%) | 119 (42.0%) | 707 (60.3%) |
| Bronchial diseases | 61 (4.2%) | 6 (2.1%) | 55 (4.7%) |
| Cancers | 25 (1.7%) | 7 (2.5%) | 18 (1.5%) |
| Cardiovascular and cerebrovascular diseases | 518 (35.6%) | 64 (22.6%) | 454 (38.7%) |
| Chronic kidney diseases | 30 (2.1%) | 5 (1.8%) | 25 (2.1%) |
| Diabetes | 229 (15.7%) | 27 (9.5%) | 202 (17.2%) |
| Digestive diseases | 113 (7.8%) | 23 (8.1%) | 90 (7.7%) |
| Other diseases | 210 (14.4%) | 34 (12%) | 176 (15.0%) |
| Illness severity | |||
| Asymptomatic | 73 (5.0%) | 26 (9.2%) | 47 (4%) |
| Mild | 1032 (70.9%) | 237 (83.7%) | 795 (67.8%) |
| Moderate | 144 (9.9%) | 11 (3.9%) | 133 (11.3%) |
| Severe or critical | 206 (14.2%) | 9 (3.2%)a | 197 (16.8%) |
| Acute phase symptoms | |||
| Fever | 989 (68.0%) | 177 (62.5%) | 812 (69.3%) |
| Cough | 702 (48.2%) | 138 (48.8%) | 564 (48.1%) |
| Dyspnea | 451 (31.0%) | 48 (17.0%) | 403 (34.4%) |
| Fatigue | 692 (47.6%) | 109 (38.5%) | 583 (49.7%) |
| Nausea or vomiting | 158 (10.9%) | 31 (11.0%) | 127 (10.8%) |
| Diarrhea | 334 (23.0%) | 70 (24.7%) | 264 (22.5%) |
| Myalgia | 292 (20.1%) | 52 (18.4%) | 240 (20.5%) |
| Smell disorders | 158 (10.9%) | 22 (7.8%) | 136 (11.6%) |
| Taste disorders | 267 (18.4%) | 46 (16.3%) | 221 (18.9%) |
| Time from symptom onset to follow-up, months | 16.9 (1.3) | 17.0 (1.3) | 16.9 (1.2) |
| COVID-19 vaccinationb | 902 (62.0%) | 186 (65.7%) | 716 (61.1%) |
Data are numbers (%) or means (SD). aAll nine severe patients were infected at the early stage of the epidemic and were home-isolated because of the limited supply of medical resources, including hospital beds. These patients moved to Fangcang shelter hospitals starting on February 2020. bSince April 2021, the Chinese government has encouraged those who have recovered from COVID-19 to take SARS-CoV-2 vaccines; therefore, all those who recovered in this study received SARS-CoV-2 vaccines after their infection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
